| Literature DB >> 17090653 |
Andrew Kim1, Kelly Morgan, Diane E Hasz, Stephen M Wiesner, Jennifer O Lauchle, Jennifer L Geurts, Miechaleen D Diers, Doan T Le, Scott C Kogan, Luis F Parada, Kevin Shannon, David A Largaespada.
Abstract
Neurofibromatosis type 1 (NF1) syndrome is caused by germline mutations in the NF1 tumor suppressor, which encodes neurofibromin, a GTPase activating protein for Ras. Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated mice given transplants with homozygous Nf1 mutant (Nf1-/-) hematopoietic stem cells develop a fatal myeloproliferative disorder (MPD) that models JMML. We investigated the requirement for signaling through the GM-CSF receptor to initiate and sustain this MPD by generating Nf1 mutant hematopoietic cells lacking the common beta chain (Beta c) of the GM-CSF receptor. Mice reconstituted with Nf1-/-, beta c-/- stem cells did not develop evidence of MPD despite the presence of increased number of immature hematopoietic progenitors in the bone marrow. Interestingly, when the Mx1-Cre transgene was used to inactivate a conditional Nf1 mutant allele in hematopoietic cells, concomitant loss of beta c-/- reduced the severity of the MPD, but did not abrogate it. Whereas inhibiting GM-CSF signaling may be of therapeutic benefit in JMML, our data also demonstrate aberrant proliferation of Nf1-/-myeloid progenitors that is independent of signaling through the GM-CSF receptor.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17090653 PMCID: PMC1794059 DOI: 10.1182/blood-2006-05-025395
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113